Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A systematic review finds Incomplete excision rates for basal cell carcinoma range from 4.7% to 20.4% against recommended guidelines of 5%.

A doctor examines moles on a woman's back

Similar stories

HIPCARE trial launches in the Philippines

Prof Matt Costa has just returned from the Philippines, where he launched the new HIPCARE trial with co-lead investigator Prof Irewin Tabu. The first of five Low- and Middle-Income Countries (LMIC) in Asia to take part, eight hospitals in the Philippines will start recruiting patients with fragility fractures of the hip to the study within weeks.